SUVENPHAR

Suven Pharmaceuticals Share PriceSuven Pharmaceuticals

₹655.35
5.95 (0.92%)
  • Advice
  • Hold
As on 30 November, 2023 | 07:09 BSE: 543064 NSE: SUVENPHARISIN: INE03QK01018

Suven Pharmaceuticals Performance

Day Range

  • Low 643.20
  • High 671.45
₹ 655.35

52 Week Range

  • Low 450.50
  • High 671.45
₹ 655.35
  • Open Price652.75
  • Previous Close649.40
  • Volume509064

Start SIP in Suven Pharmaceuticals

Start SIP

Suven Pharmaceuticals Share Price

  • Over 1 Month 15.31%
  • Over 3 Month 29.12%
  • Over 6 Month 37.23%
  • Over 1 Year 42.33%

Suven Pharmaceuticals Key Statistics

P/E Ratio 38.6
PEG Ratio 326.5
Market Cap Cr 16,683
Price to Book Ratio 9.6
EPS 16.6
Dividend 0
Relative Strength Index 76.22
Money Flow Index 91.2
MACD Signal 10.87
Average True Range 21.95

Suven Pharmaceuticals Investment Rating

  • Master Rating:
  • Suven Pharmaceuticals has an operating revenue of Rs. 1,301.73 Cr. on a trailing 12-month basis. An annual revenue de-growth of -2% needs improvement, Pre-tax margin of 42% is great, ROE of 23% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 13% and 28% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 8% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 86 which is a GOOD score indicating consistency in earnings, a RS Rating of 67 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 70 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Suven Pharmaceuticals Financials
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 225344364348278339364
Operating Expenses Qtr Cr 127174190201172184206
Operating Profit Qtr Cr 97170175147107155158
Depreciation Qtr Cr 10111111111110
Interest Qtr Cr 1121012
Tax Qtr Cr 26434238274055
Net Profit Qtr Cr 7512413010979114224
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 1,3751,508
Operating Expenses Annual Cr 747740
Operating Profit Annual in Cr 583580
Depreciation Cr 4339
Interest Annual Cr 56
Tax Annual Cr 147164
Net Profit Annual Cr 433558
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 270
Cash from Investing Activity Annual Cr -90
Cash from Financing Annual Activity Cr -156
Net Cash Flow Annual Cr 23
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 1,7491,521
Fixed Assets Annual Cr 677564
Total Non Current Assets Annual Cr 1,003696
Total Current Assets Annual Cr 9551,109
Total Assets Annual Cr 1,9581,805
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 6960
ROE Annual % 2537
ROCE Annual % 3246
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 4758
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 231348369354278339364
Operating Expenses Qtr Cr 133181200207179188207
Operating Profit Qtr Cr 98167169147100151157
Depreciation Qtr Cr 12131212121210
Interest Qtr Cr 1121012
Tax Qtr Cr 26434238264170
Net Profit Qtr Cr 801211241087210892
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 1,3871,413
Operating Expenses Annual Cr 774741
Operating Profit Annual in Cr 567579
Depreciation Cr 4839
Interest Annual Cr 56
Tax Annual Cr 148214
Net Profit Annual Cr 411454
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 330
Cash from Investing Activity Annual Cr -136
Cash from Financing Annual Activity Cr -156
Net Cash Flow Annual Cr 37
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 1,7351,527
Fixed Assets Annual Cr 828564
Total Non Current Assets Annual Cr 955702
Total Current Assets Annual Cr 1,0111,128
Total Assets Annual Cr 1,9661,830
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 6860
ROE Annual % 2430
ROCE Annual % 3139
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 4651

Suven Pharmaceuticals Technicals

EMA & SMA

Current Price
₹655.35
5.95 (0.92%)
pointer
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹598.33
  • 50 Day
  • ₹573.95
  • 100 Day
  • ₹548.27
  • 200 Day
  • ₹522.46
  • 20 Day
  • ₹589.11
  • 50 Day
  • ₹574.00
  • 100 Day
  • ₹537.66
  • 200 Day
  • ₹507.12

Suven Pharmaceuticals Resistance and Support

PIVOT
₹656.67
Resistance
First Resistance 670.13
Second Resistance 684.92
Third Resistance 698.38
RSI 76.22
MFI 91.20
MACD Single Line 10.87
MACD 18.17
Support
First Resistance 641.88
Second Resistance 628.42
Third Resistance 613.63

Suven Pharmaceuticals Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 529,340 20,024,932 37.83
Week 670,798 26,798,380 39.95
1 Month 348,766 17,326,674 49.68
6 Month 486,231 31,634,208 65.06

Suven Pharmaceuticals Result Highlights

Suven Pharmaceuticals Synopsis

NSE-Medical-Generic Drugs

Suven Pharmaceutical is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1330.08 Cr. and Equity Capital is Rs. 25.46 Cr. for the Year ended 31/03/2023. Suven Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 06/11/2018 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24299TG2018PLC128171 and registration number is 128171.
Market Cap 16,683
Sales 1,282
Shares in Float 10.18
No of funds 154
Yield 0.18
Book Value 9.54
U/D Vol ratio 2.9
LTDebt / Equity 2
Alpha 0.15
Beta 0.07

Suven Pharmaceuticals

Owner NameSep-23Jun-23Mar-23Dec-22
Promoters 60%60%60%60%
Mutual Funds 12.15%9.12%8.56%8.97%
Insurance Companies 1.38%0.11%2.26%2.23%
Foreign Portfolio Investors 10.01%9.5%9.47%8.11%
Financial Institutions/ Banks
Individual Investors 11.76%12.8%12.76%14.01%
Others 4.7%8.47%6.95%6.68%

Suven Pharmaceuticals Management

Name Designation
Mr. Venkateswarlu Jasti Managing Director
Ms. Deepanwita Chattopadhyay Independent Director
Dr. Jerry Jeyasingh Non Exe.Non Ind.Director
Mr. J V Ramudu Chairman, Non Ind & Non Exe Director
Mr. D G Prasad Independent Director
Dr. V Sambasiva Rao Independent Director

Suven Pharmaceuticals Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Suven Pharmaceuticals Corporate Action

Date Purpose Remarks
2023-11-09 Quarterly Results
2023-08-08 Quarterly Results
2023-05-25 Audited Results
2023-02-06 Quarterly Results
2022-11-08 Quarterly Results
Date Purpose Remarks
2022-09-12 INTERIM Rs.1.00 per share(100%)Interim Dividend
2022-09-12 SPECIAL Rs.5.00 per share(500%)Special Dividend
2022-05-17 INTERIM Re.1.00 per shaer (100%) Second Interim Dividend
2022-05-17 SPECIAL Rs.1.00 per share(100%)Special Dividend
2022-02-16 INTERIM Rs.1.00 per share(100%)Interim Dividend

Suven Pharmaceuticals MF Shareholding

Name Amount(cr)
UTI Flexi Cap Fund Regular Plan Growth 24,370
Axis Small Cap Fund Regular Growth 16,369
DSP ELSS Tax Saver Fund Regular Plan Growth 11,693
HSBC Small Cap Fund Fund Regular Growth 11,552
Quant Small Cap Fund Growth 9,521

Suven Pharmaceuticals FAQs

What is Share Price of Suven Pharmaceuticals ?

Suven Pharmaceuticals share price is ₹655 As on 30 November, 2023 | 06:55

What is the Market Cap of Suven Pharmaceuticals ?

The Market Cap of Suven Pharmaceuticals is ₹16682.9 Cr As on 30 November, 2023 | 06:55

What is the P/E ratio of Suven Pharmaceuticals ?

The P/E ratio of Suven Pharmaceuticals is 38.6 As on 30 November, 2023 | 06:55

What is the PB ratio of Suven Pharmaceuticals ?

The PB ratio of Suven Pharmaceuticals is 9.6 As on 30 November, 2023 | 06:55

Q2FY23